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Objective: Report an unusual cause of thrombocytopenia in a burn patient and provide
a brief review of causes of thrombocytopenia in critically ill patients. Methods: Case
report format and selected review of PubMed search including the search terms throm-
bocytopenia, critical illness, and vancomycin. Results: Reports of vancomycin-induced
thrombocytopenia are uncommon. Conclusion: Drug-induced thrombocytopenia is a
rare but important consideration in the evaluation of thrombocytopenia in critically ill
patients. An increasing number of patients are treated with potentially causative agents
including vancomycin and the diagnosis may be easily overlooked.
Thrombocytopenia is a relatively common finding in critically ill patients. Many po-
tentialcausesarefrequentandsimultaneouslypresentinanygivenpatientandlesscommon
causes including drug-induced mechanisms can easily be overlooked. We present a case of
a rarely encountered but important consideration in the differential diagnosis of thrombo-
cytopenia.
CASE REPORT
A 60-year-old gentleman with a past medical history of essential hypertension, dyslipi-
demia, and stable coronary artery disease was admitted with steam burns to 40% of total
body surface area involving his abdomen, bilateral lower extremities, and bilateral up-
per extremities. He had been working as a pipe fitter attempting to repair underground
steam pipes when the mishap occurred. Medications at the time of admission included
aspirin, hydrochlorothiazide, and atorvastatin. He had no known allergies to medications.
His burn wounds were successfully excised and grafted with good results. However, his
hospital course was complicated by acute renal failure requiring dialysis and ventilator-
associated pneumonia with respiratory failure leading to tracheostomy and prolonged ven-
tilator dependence. His pneumonia was treated initially with intravenous vancomycin and
piperacillin/tazobactam. Methicillin-resistant Staphylococcus aureus was isolated from the
sputumandantibioticcoveragewastailoredwithdiscontinuationofpiperacillin/tazobactam.
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Treatment with vancomycin was continued for 14 days. Several days after completion of
antibiotictherapythepatientcontinuedtohaveclinicalsignsofinfectionincludingelevated
white blood cell count, fever, increased sputum production, lack of improvement in arterial
to inspired oxygen ratio, and a persistent, albeit subtle infiltrate on chest radiograph. Prior
sputum cultures had also demonstrated the presence of a resistant Acinetobacter species
known to be an occasional colonizing organism in our intensive care unit. Failed treatment
of ventilator-associated pneumonia and tracheobronchitis were considered as possible ex-
planations for the clinical picture. Fiberoptic bronchoscopy with bronchoalveolar lavage
was performed. Initial gram stain of the lavage fluid revealed gram-positive cocci, and
vancomycin was restarted. The following day, vancomycin was discontinued and therapy
with linezolid was initiated. At the time vancomycin was restarted the platelet count was
268,000/mm3. Over the next 3 days the platelet count dropped precipitously to a nadir of
10,000/mm3. On examination, mild, spontaneous bleeding was evident around the dial-
ysis catheter and oozing was present from several healing wounds. Laboratory analysis
results included prothrombin time 12.9 seconds, international normalized ratio 1.3; par-
tial tissue thromboplastin time 30.1 seconds, ratio 1.0; fibrinogen 483 mg/dL and fibrin
degradation products less than 10 μg/ml. An assay for heparin-induced antibodies was
negative. Given the clinical scenario and evidence of spontaneous bleeding, platelet trans-
fusionwasattemptedwithminimalhematologicandclinicalresponse.Adiagnosisofdrug-
induced thrombocytopenia was considered as was idiopathic thrombocytopenic purpura.
Bronchoalveolar lavage fluid grew diagnostic quantities of Staphylococcus aureus sensi-
tive to macrolide antibiotics and therapy was continued with azithromycin. Therapy with
corticosteroids was initiated without improvement. The platelet count eventually recovered
to levels above 50,000/mm3 after 10 days while patient was continued on dialysis for acute
renal failure (Fig 1). A careful review of possible offending agents led to vancomycin as
a presumptive cause of thrombocytopenia. Testing for vancomycin-dependent antiplatelet
antibodieswasrequestedandrevealedthepresenceofIgGvancomycin-dependent,platelet-
reactive antibodies. These finding are consistent with a diagnosis of vancomycin-induced
immune thrombocytopenia.1
DISCUSSION
Thrombocytopenia defined as a platelet count less than 100,000/mm3, is a relatively com-
mon finding occurring in up to 35% of patients in the surgical intensive care units.2
Thrombocytopenia can occur as the result of impaired platelet production or increased
consumption. Consumption may be related to both nonimmunologic and immunologic
mechanisms. The differential diagnosis of thrombocytopenia in the intensive care unit is
summarized in Table 1. The most frequent causes in this population are sepsis and dissemi-
nated intravascular coagulation accounting for more than 75% of all cases. Other causes of
thrombocytopenia in the intensive care unit include dilutional thrombocytopenia from mas-
sive blood loss (8%); thrombotic microangiopathy (thrombotic thrombocytopenic purpura,
hemolytic-uremic syndrome, severe malignant hypertension, and chemotherapy-induced
microangiopathy)(1%);heparin-inducedthrombocytopenia(1%);immunethrombocytope-
nia (3%); and drug-induced thrombocytopenia (10%).3 Drug-induced thrombocytopenia
can occur due to decreased platelet production, that is, bone marrow toxicity or due to an
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Figure 1. Platelet count following repeat treatment with vancomycin. Note the duration of
significant thrombocytopenia in the setting of renal failure.
Table 1. Causes of thrombocytope-








immune-mediated increase in platelet destruction.4 Aster has recently reviewed the mech-
anisms of immune-mediated platelet destruction.5,6 Mechanisms of immune-mediated
platelet destruction include interactions of hapten-dependent antibodies as well as drug-
specificantibodies,drug-inducedautoantibodies,andimmunecomplex-mediatedpathways.
Recovery of the platelet count is anticipated after withdrawal of the offending agent.
Vancomycin is frequently employed in the treatment of gram-positive bacterial in-
fections and has become a mainstay in the treatment of serious infections in hospitalized
patients.Reportsimplicatingvancomycinasacausalagentofthrombocytopeniaarerare.7,8
VonDrygalskiandothersrecentlyreportedaseriesofpatientswiththrombocytopenia,who
had been referred for testing of vancomycin-dependent, platelet-reactive antibodies be-





in the intensive care unit. The diagnosis of drug-induced thrombocytopenia is often diffi-
cult in intensive care unit patients. Frequently, there is more than 1 potential cause for a
low platelet count and a number of potential causative agents may have been administered.
In this case, the patient received a short course of linezolid before antibiotic therapy was
de-escalated based on culture results. Although linezolid is known to be associated with
thrombocytopenia, the majorities of cases reported are dependent on duration of therapy
and are easily reversible on discontinuing the drug.9 Arriving at the correct diagnosis is
based on ruling out common causes and reviewing the timing of onset of thrombocytope-
nia with potentially offending agents. George has reviewed the evidence for and serially
updated agents associated with drug-induced thrombocytopenia.10−12 The peripheral blood
smear can be useful in evaluating for the presence of microangiopathic processes. Bone
marrow studies may be useful in selected patients. Serology may be important where assays
are available for specific antibodies. Care must be taken, however, in interpretation of an-
tiplatelet antibodies alone when heparin-induced thrombocytopenia is considered. In this,
patient laboratory testing and the clinical scenario ruled out the most frequent causes of
thrombocytopeniainthecriticallyill.Failuretoachieveasustainedincreaseinplateletcount
afterplatelettransfusionwasconsistentwithplateletdestructionastheprimarymechanism.
Heparin-induced thrombocytopenia (HIT) has been extensively reviewed in the literature
and is a frequent consideration in hospitalized patients with low platelet counts. In this
instance heparin-induced mechanisms were considered but rejected based on the clinical
pictureandsubsequentnegativeserology.AlthoughHITisamajorconcerninacriticallyill
patient due to almost universal exposure to the drug, it is diagnosed very infrequently.13,14
A simple model named the “4 T’s” system was created and validated to assess the pretest
probabilityofadiagnosisofHIT.15 The4Tsincludedegreeofthrombocytopenia,timingof
clinical sequelae, thrombosis in vascular beds, and other possible explanations for throm-
bocytopenia. On the basis of this model, the patient had a low-to-intermediate probability
of HIT on clinical grounds and with further laboratory assays negative for antibodies, HIT
was very unlikely.16
Further search for possible causative agents placed vancomycin at the top of the list.
This was later confirmed by the demonstration of vancomycin-dependent antiplatelet anti-
bodies.Thedelayedrecoveryafterdiscontinuationofvancomycinisconsistentwithdelayed
drugclearanceduetorenalfailureandwasobservedinthevonDrygalskistudy.1 Thisreport
highlights the importance of maintaining an index of suspicion for drug-induced mecha-
nismsasacauseforthrombocytopeniainpatientstreatedwithvancomycin.Thismechanism
may be overlooked in the critically ill burn patient because thrombocytopenia can often be
attributed to multiple other causes.
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